12/23
04:14 pm
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/17
11:56 am
xncr
Incyte announces EU approval of Xencor-partnered lymphoma therapy [Seeking Alpha]
Medium
Report
Incyte announces EU approval of Xencor-partnered lymphoma therapy [Seeking Alpha]
12/17
07:06 am
xncr
Xencor (NASDAQ:XNCR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Xencor (NASDAQ:XNCR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/16
04:43 pm
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/10
04:12 am
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/9
07:00 am
xncr
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
Medium
Report
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
12/2
03:47 pm
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
09:04 am
xncr
Xencor (NASDAQ:XNCR) was given a new $29.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Xencor (NASDAQ:XNCR) was given a new $29.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
xncr
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/18
01:23 pm
xncr
Xencor (NASDAQ:XNCR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Xencor (NASDAQ:XNCR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/14
06:51 am
xncr
Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings [Yahoo! Finance]
Medium
Report
Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings [Yahoo! Finance]
11/10
04:01 pm
xncr
Xencor to Participate at Upcoming Investor Conferences
Medium
Report
Xencor to Participate at Upcoming Investor Conferences
11/6
05:51 pm
xncr
Xencor (NASDAQ:XNCR) had its price target lowered by analysts at JPMorgan Chase & Co. from $20.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
Xencor (NASDAQ:XNCR) had its price target lowered by analysts at JPMorgan Chase & Co. from $20.00 to $18.00. They now have an "overweight" rating on the stock.
11/6
01:21 pm
xncr
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Low
Report
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
11/6
11:43 am
xncr
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Royal Bank Of Canada from $18.00 to $19.00. They now have an "outperform" rating on the stock.
Medium
Report
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Royal Bank Of Canada from $18.00 to $19.00. They now have an "outperform" rating on the stock.
11/6
10:02 am
xncr
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Cantor Fitzgerald from $40.00 to $42.00. They now have an "overweight" rating on the stock.
Medium
Report
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Cantor Fitzgerald from $40.00 to $42.00. They now have an "overweight" rating on the stock.
11/5
04:01 pm
xncr
Xencor Reports Third Quarter 2025 Financial Results
Low
Report
Xencor Reports Third Quarter 2025 Financial Results
10/29
06:02 am
xncr
Xencor (NASDAQ:XNCR) was upgraded by analysts at Barclays PLC to an "overweight" rating.
Medium
Report
Xencor (NASDAQ:XNCR) was upgraded by analysts at Barclays PLC to an "overweight" rating.
10/29
06:01 am
xncr
Xencor (NASDAQ:XNCR) was given a new $23.00 price target on by analysts at Barclays PLC.
Medium
Report
Xencor (NASDAQ:XNCR) was given a new $23.00 price target on by analysts at Barclays PLC.
10/27
10:07 am
xncr
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/24
05:38 pm
xncr
Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript [Seeking Alpha]
Medium
Report
Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript [Seeking Alpha]
10/24
12:30 pm
xncr
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
Low
Report
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
10/21
08:01 am
xncr
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Medium
Report
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
10/14
12:45 pm
xncr
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Medium
Report
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/14
12:17 pm
xncr
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.